

ABSTRACT OF THE DISCLOSURE

Chimeric and humanized IL4 MAbs derived from affinity MAbs, pharmaceutical compositions containing same, and methods of treatment are provided.

09879451.061201  
T02T90" T945/860

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> C07K 16/24, 16/46, 17/02, C07H 15/12, G01N 33/53, C12P 21/08, C12N 5/10, 5/20, 15/13, A61K 39/395	<b>A1</b>	<b>(11) International Publication Number:</b> WO 95/07301 <b>(43) International Publication Date:</b> 16 March 1995 (16.03.95)
<b>(21) International Application Number:</b> PCT/US94/10308 <b>(22) International Filing Date:</b> 7 September 1994 (07.09.94) <b>(30) Priority Data:</b> 08/117,366 7 September 1993 (07.09.93) US 08/136,783 14 October 1993 (14.10.93) US <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 08/136,783 (CIP) Filed on 14 October 1993 (14.10.93) <b>(71) Applicants (for all designated States except US):</b> SMITHK- LINE BEECHAM CORPORATION [US/US]; Corporate In- tellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US). SMITHK- LINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford TW8 9BD (GB). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HOLMES, Stephen, Dud- ley [GB/GB]; Yew Tree Bottom Road, Epsom, Surrey KT15 5XQ (GB). GROSS, Mitchell, Smart [US/US]; 667 Pugh		<b>(74) Agents:</b> SUTTON, Jeffrey, A. et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).  <b>(81) Designated States:</b> AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
<b>(54) Title:</b> RECOMBINANT IL4 ANTIBODIES USEFUL IN TREATMENT OF IL4 MEDIATED DISORDERS  <b>(57) Abstract</b>  Chimeric and humanized IL4 MAb derived from high affinity MAb, pharmaceutical compositions containing same, and methods of treatment are provided.		